# Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

> **NCT05116046** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 35 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **BIOLOGICAL:** Recifercept

## Key facts

- **NCT ID:** NCT05116046
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-24
- **Primary completion:** 2022-12-16
- **Final completion:** 2023-03-30
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.
- **Last updated:** 2024-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116046, "Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT05116046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*